Persistent drug-induced parkinsonism in patients with normal dopamine transporter imaging

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Hong, Jin Yong ^a   Sunwoo, Mun Kyung ^b   Oh, Jungsu S ^c   Kim, Jae Seung ^c   Sohn, Young H ^d   Lee, Phil Hyu ^d  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b Bundang Jesaeng Hospital   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER;

ADULT; AGE; AGED; ANTERIOR PUTAMEN; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DRUG INDUCED PARKINSONISM; FEMALE; FUNCTIONAL NEUROIMAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; POSTERIOR PUTAMEN; PUTAMEN; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; VENTRAL STRIATUM; VERY ELDERLY; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; METABOLISM; PROCEDURES;

AGED; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84975784053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157410     Document Type: Article

References (37)

1. Barbosa MT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord. 2006; 21(6):800-8. doi: 10.1002/mds.20806 PMID: 16482566.
2. Benito-Leon J, Bermejo-Pareja F, Rodriguez J, Molina JA, Gabriel R, Morales JM, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003; 18 (3):267-74. doi: 10.1002/mds.10362 PMID: 12621629.
3. Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. European journal of nuclear medicine and molecular imaging. 2010; 37(3):556-64. doi: 10.1007/s00259-009-1289-4 PMID: 19862520.
4. Tinazzi M, Cipriani A, Matinella A, Cannas A, Solla P, Nicoletti A, et al. [(1)(2)(3)I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophr Res. 2012; 139(1-3):40-5. doi: 10.1016/j.schres.2012.06.003 PMID: 22727453.
5. Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: A double-hit hypothesis? Mov Disord. 2015; 30(6):780-5. doi: 10.1002/mds.26209 PMID: 25801826.
6. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord. 2006; 21 (4):510-4. doi: 10.1002/mds.20748 PMID: 16250023.
7. Shin HW, Kim JS, Oh M, You S, Kim YJ, Kim J, et al. Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography. Neurol Sci. 2015; 36(2):269-74. doi: 10.1007/ s10072-014-1945-8 PMID: 25231645.
8. Cuberas-Borros G, Lorenzo-Bosquet C, Aguade-Bruix S, Hernandez-Vara J, Pifarre-Montaner P, Miquel F, et al. Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and parkinsonism. Clin Nucl Med. 2011; 36(11):991-6. doi: 10.1097/RLU.0b013e3182291a7b PMID: 21975386.
9. Vlaar AM, de Nijs T, Kessels AG, Vreeling FW, Winogrodzka A, Mess WH, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol. 2008; 59(5):258-66. doi: 10.1159/000115640 PMID: 18264015.
10. Olivares Romero J, Arjona Padillo A. Diagnostic accuracy of 123 I-FP-CIT SPECT in diagnosing druginduced parkinsonism: a prospective study. Neurologia. 2013; 28(5):276-82. doi: 10.1016/j.nrl.2012. 05.005 PMID: 22795922.
11. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology. 1993; 43(3 Pt 1):552-6. PMID: 8451000.
12. Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord. 2008; 23(13):1825-9. doi: 10.1002/mds.22098 PMID: 18759353.
13. Kim JS, Oh YS, Kim YI, Yang DW, Chung YA, You Ie R, et al. Combined use of (1)(2)(3)I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): a 2-year follow-up study. Archives of gerontology and geriatrics. 2013; 56(1):124-8. doi: 10.1016/j.archger.2012.05.001 PMID: 22633343.
14. Goetz CG. Drug-induced Parkinsonism and idiopathic Parkinson's disease. Arch Neurol. 1983; 40 (5):325-6. PMID: 6133514.
15. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Journal of neurology, neurosurgery, and psychiatry. 1988; 51(6):850-4. PMID: 2900293; PubMed Central PMCID: PMCPMC1033159.
16. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet. 1984; 2(8411):1082-3. PMID: 6150149.
17. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol. 1982; 39(10):644-6. PMID: 6127066.
18. Shuaib UA, Rajput AH, Robinson CA, Rajput A. Neuroleptic-induced Parkinsonism: Clinicopathological study. Movement disorders: official journal of the Movement Disorder Society. 2016; 31(3):360-5. doi: 10.1002/mds.26467 PMID: 26660063.
19. Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012; 8(1):15-21. doi: 10.3988/jcn. 2012.8.1.15 PMID: 22523509; PubMed Central PMCID: PMCPMC3325428.
20. Foubert-Samier A, Helmer C, Perez F, Le Goff M, Auriacombe S, Elbaz A, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology. 2012; 79(15):1615-21. doi: 10.1212/WNL.0b013e31826e25ce PMID: 23019267.
21. Jimenez-Jimenez FJ, Orti-Pareja M, Ayuso-Peralta L, Gasalla T, Cabrera-Valdivia F, Vaquero A, et al. Drug-induced parkinsonism in a movement disorders unit: A four-year survey. Parkinsonism & related disorders. 1996; 2(3):145-9. PMID: 18591033.
22. Oh M, Kim JS, Kim JY, Shin KH, Park SH, Kim HO, et al. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiplesystem atrophy. J Nucl Med. 2012; 53(3):399-406. doi: 10.2967/jnumed.111.095224 PMID: 22323779.
23. Hong JY, Oh JS, Lee I, Sunwoo MK, Ham JH, Lee JE, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology. 2014; 82(18):1597-604. doi: 10.1212/WNL.0000000000000385 PMID: 24719485.
24. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001; 21(9):1034-57. Epub 2001/08/29. doi: 10.1097/00004647-200109000-00002 PMID: 11524609.
25. Oh JS, Oh M, Chung SJ, Kim JS. Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia. Neuroreport. 2014; 25(15):1198-202. doi: 10.1097/WNR.0000000000000247 PMID: 25144395.
26. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27(9):1533-9. Epub 2007/05/24. doi: 10.1038/sj.jcbfm.9600493 PMID: 17519979.
27. Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J. How useful is [123I]beta-CIT SPECT in clinical practice? Journal of neurology, neurosurgery, and psychiatry. 2005; 76(9):1211-6. doi: 10.1136/jnnp. 2004.045237 PMID: 16107353; PubMed Central PMCID: PMC1739796.
28. Rollema H, Skolnik M, D'Engelbronner J, Igarashi K, Usuki E, Castagnoli N Jr. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. The Journal of pharmacology and experimental therapeutics. 1994; 268(1):380-7. PMID: 8301579.
29. Bishnoi M, Chopra K, Kulkarni SK. Protective effect of adenosine reuptake inhibitors in haloperidolinduced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Pharmacology. 2007; 79(3):171-83. doi: 10.1159/000100924 PMID: 17377417.
30. Levinson AJ, Garside S, Rosebush PI, Mazurek MF. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience. 1998; 84(1):201-11. PMID: 9522374.
31. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. The American journal of psychiatry. 1998; 155 (9):1207-13. PMID: 9734544.
32. Meredith GE, Switzer RC 3rd, Napier TC. Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum. Brain Res. 2004; 995(1):14-22. PMID: 14644466.
33. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991; 114 (Pt 5):2283-301. PMID: 1933245.
34. Rinne JO, Laine M, Kaasinen V, Norvasuo-Heila MK, Nagren K, Helenius H. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology. 2002; 58(10):1489-93. PMID: 12034784.
35. Rinne JO, Sahlberg N, Ruottinen H, Nagren K, Lehikoinen P. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology. 1998; 50(1):152-6. PMID: 9443472.
36. Chiba S, Takada E, Tadokoro M, Taniguchi T, Kadoyama K, Takenokuchi M, et al. Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy. Neurobiol Aging. 2012; 33 (10):2491-505. doi: 10.1016/j.neurobiolaging.2011.11.002 PMID: 22169201.
37. Horvath J, Burkhard PR, Herrmann FR, Bouras C, Kovari E. Neuropathology of parkinsonism in patients with pure Alzheimer's disease. J Alzheimers Dis. 2014; 39(1):115-20. doi: 10.3233/JAD-131289 PMID: 24121968.